DrugPatentWatch Database Preview

Details for Patent: 10,342,762

« Back to Dashboard

Which drugs does patent 10,342,762 protect, and when does it expire?

Patent 10,342,762 protects DSUVIA and is included in one NDA.

This patent has seventy patent family members in twelve countries.

Summary for Patent: 10,342,762

Title:	Small-volume oral transmucosal dosage forms
Abstract:	Small-volume oral transmucosal dosage forms or NanoTabs.RTM. comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs.RTM. to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Lawrence (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	14/296,992
Patent Claim Types: see list of patent claims	Composition; Delivery; Device; Dosage form;

Drugs Protected by US Patent 10,342,762

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acelrx Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes			Y

International Family Members for US Patent 10,342,762

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	474564
Canada	2636088
Canada	2636115
Canada	2636119
Canada	2673837